Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Novartis' TREM2 drug fails Phase 2 ALS trial

Novartis has scrapped development of a Phase 2 treatment candidate for amyotrophic lateral sclerosis, Endpoints News has learned. The Swiss pharma giant is ending work on VHB937/lifonebart in ALS, according to a

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at endpoints.news →

More in Health & Medicine

More from Wednesday 16 September →